Since more than 70％ of clinically used drugs are excreted from the body through metabolic processes, drug metabolism is a key determinant of pharmacokinetics, drug response and drug toxicity. Much progress has been made in understanding drug-drug interactions via the inhibition or induction of cytochrome P450s (P450, CYP), as well as the eŠects of genetic polymorphisms of P450s on pharmacokinetics, and this has facilitated the progress of optimized pharmacotherapy in the clinic. Now, similar information is needed for non-CYP enzymes, especially concerning Phase I enzymes, based on advanced basic and clinical studies. Recently, it was revealed that post-transcriptional regulation by microRNAs or RNA editing plays a signiˆcant role in regulating the expression of drug-metabolizing enzymes, thus conferring variability in the detoxiˆcation and metabolic activation of drugs or chemicals. Changes in the expression proˆle of microRNAs in tissues or body ‰uids can be a biomarker of drug response and toxicity; therefore, such studies could also be useful for drug repositioning. In addition, microRNAs are involved in pharmacogenetics, because single nucleotide polymorphisms in microRNA binding sites of mRNAs, or microRNAs themselves, may cause changes in gene expression. Some microRNA-related polymorphisms could be biomarkers of the clinical outcome of pharmacotherapy. In this review article, recent progress and future directions for drug metabolism studies are discussed.
. Induction Mechanisms of Cytochrome P450s
Nuclear receptors or transcription factors, which are activated by a ligand or compound, bind to a speciˆc responsive element at the 5′ -upstream region to activate the transcription of P450s. AhR: aryl hydrocarbon receptor; Arnt: AhR nuclear translocator; Hsp90: heat shock protein 90; CAR: constitutive androstane receptor; PXR: pregnane X receptor; PPAR: peroxisome proliferator-activated receptor; RXR: retinoid X receptor; XRE: xenobiotic responsive element; PBREM: phenobarbital responsive enhancer module; XREM: xenobiotic responsive enhancer module; PPRE, PPAR response element.
Fig. 3. Transcriptional or Post-transcriptional Regulation of Cytochrome P450s
In addition to the transcriptional regulation via transcription factors, post-transcriptional regulation via microRNAs signiˆcantly contribute to control the expression of cytochrome P450s. microRNAs, short non-coding RNAs, bind primarily to the 3′ -untranslated region of the target mRNA to facilitate mRNA degradation or repress translation. 
Fig. 5. Impact of A-to-I RNA Editing on Human AhR and Its Downstream Gene Expression
There is a large interindividual variability ( 220-fold) in the ADAR1 expression in the human livers. In the 3′ -UTR of human AhR mRNA, multiple A-to-I RNA editing sites were identiˆed. The editing creates a sequence to which miR-378 binds to down-regulate AhR, followed by decreased CYP1 transactivation. 
